Tissue Regenix Group plc
TRX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £27,592 | £53,000 | £58,052 | £46,669 |
| - Cash | £1,075 | £1,870 | £3,461 | £4,650 |
| + Debt | £10,999 | £10,465 | £10,472 | £9,395 |
| Enterprise Value | £37,516 | £61,595 | £65,063 | £51,414 |
| Revenue | £13,796 | – | £12,968 | £4,521 |
| % Growth | – | – | 186.9% | – |
| Gross Profit | £5,770 | – | £6,814 | £2,498 |
| % Margin | 41.8% | – | 52.5% | 55.3% |
| EBITDA | £5 | – | £829 | £234 |
| % Margin | 0% | – | 6.4% | 5.2% |
| Net Income | -£934 | – | -£222 | -£643 |
| % Margin | -6.8% | – | -1.7% | -14.2% |
| EPS Diluted | -0.014 | – | -0.003 | -0.009 |
| % Growth | – | – | 65.9% | – |
| Operating Cash Flow | -£202 | £0 | -£1,366 | £1,365 |
| Capital Expenditures | -£50 | £0 | -£206 | -£154 |
| Free Cash Flow | -£252 | £0 | -£1,573 | £1,211 |